

# Biologics Outsourcing Market Report 2024-2031 | Industry Growth, Key Players & Forecast

*The Biologics Outsourcing Market is rapidly growing, driven by increasing demand for biopharmaceuticals and cost-effective manufacturing solutions globally.*

AUSTIN, TX, UNITED STATES, May 28, 2025 /EINPresswire.com/ -- Biologics Outsourcing Market Value and Growth Outlook

The [Biologics Outsourcing Market Size](#) was projected to grow at a compound annual growth rate (CAGR) between 2024 and 2031.



The image shows the cover of a report titled "Biologics Outsourcing Market" by Data Intelligence. The cover features a photograph of three scientists in a laboratory setting, with one scientist using a pipette. The Data Intelligence logo is in the top left corner. The title "Biologics Outsourcing Market" is prominently displayed in the center. Below the title, it lists "Key Benefits of Market" including: Actionable Market Insights, Competitive Intelligence Reports, and Accelerate Market Entry. At the bottom, there is a contact email: Info@datamintelligence.com. The overall design is professional with a blue and white color scheme and a green and orange bar at the top right.

To Download Sample Report: <https://datamintelligence.com/download-sample/biologics-outsourcing-market>

“

The US Biologics Outsourcing Market is expanding due to rising biopharmaceutical demand, cost efficiency needs, and advancements in biologics manufacturing technologies.”

*DataM Intelligence*

## Regional Insights

### North America

North America continues to dominate the biologics outsourcing space, driven by a robust pharmaceutical industry, early adoption of biologics, and significant R&D spending. The U.S. plays a crucial role due to the presence of several top-tier biologics contract development and manufacturing organizations (CDMOs).

### Asia-Pacific

Asia-Pacific is the fastest-growing region, offering

competitive manufacturing costs, skilled labor, and increasing government support for

biopharmaceutical innovation. Countries like India, South Korea, and China are building large-scale biologics production infrastructure, attracting global partnerships.

## Europe

Europe maintains a stable share, benefiting from a well-established healthcare regulatory environment and a strong emphasis on biosimilar development. Germany, Switzerland, and the UK remain major contributors to biologics research and manufacturing services.

## Competitive Landscape

AbbVie Inc.

Thermo Fisher Scientific Inc.

Boehringer Ingelheim GmbH

Lonza Group Ag

Catalent Inc.

Sartorius Stedim Biotech S.A.

Charles River Laboratories International Inc.

WuXi Biologics Inc.

Samsung Biologics Co. Ltd.

Emergent BioSolutions Inc.

CordenPharma GmbH

Ajinomoto Bio-Pharma Services

Syngene International Limited

Rentschler Biopharma SE

Albany Molecular Research Inc.

## Market Segmentation:

By Product: Antibodies, Vaccines, Cell and Gene Therapies, Recombinant Proteins, Others

By Service: Process Development, Cell Development, cGMP Manufacturing, Analytical Testing, Others

By Source: Mammalian, Microorganisms

By Application: Infectious Diseases, Vaccine Development, Cell And Gene Therapy, Blood Related Product Development, Stem Cell Research, Oncology, Immunological Disorders, Others

By End-User: Pharmaceutical Companies, Biotechnology Companies, Research Organizations and Academia, Others

By Region: North America, Europe, South America, Asia Pacific, Middle East, and Africa

Latest News from the USA

In the U.S., there is a growing emphasis on bringing biologics manufacturing back domestically to strengthen local production capabilities. Recent trends show pharmaceutical companies increasingly partnering with domestic CDMOs to minimize reliance on overseas suppliers. This move is partly driven by strategic national interests, particularly in ensuring supply chain resilience and readiness for public health emergencies.

One of the most notable developments includes the expansion of biomanufacturing facilities in the U.S. The Midwest and South regions are attracting attention due to attractive tax benefits and expanding pools of skilled biotech professionals. Furthermore, a wave of acquisitions has strengthened domestic capabilities. U.S.-based startups are also gaining traction, particularly those offering modular manufacturing technologies for biologics.

Additionally, there is growing legislative momentum around securing the biologics supply chain, leading to an increased number of government-funded projects aimed at boosting in-house manufacturing. These shifts have created a more favorable environment for biologics CDMOs operating in the U.S.

#### Latest News from Japan

Japan has emerged as a major player in the biologics outsourcing market, supported by a combination of scientific innovation and supportive health policies. In recent months, Japanese pharmaceutical companies have increased partnerships with global CDMOs to accelerate the development of monoclonal antibodies and vaccines.

Several new bioproduction facilities have been announced, with a focus on integrating automation, AI-driven manufacturing, and environmentally sustainable practices. Japan is also experiencing a rise in demand for biologic therapies targeting rare and complex diseases, which has driven interest in outsourced R&D and testing services.

Industry events in Tokyo and Osaka are drawing significant international attention, further positioning Japan as a hub for biologics innovation. Moreover, new government funding programs are helping local companies expand their biologics portfolios and adopt global quality standards.

The Japanese market is particularly focused on biosimilars and next-generation therapeutic proteins, making it a strong partner for global companies seeking regulatory-compliant, high-quality biologics development.

#### Conclusion

The biologics outsourcing market is set to expand significantly through 2025 and beyond. As biologic drugs become more complex and widely used, outsourcing continues to provide the expertise, scalability, and speed required to bring these therapies to market. With dynamic developments in the USA and Japan, the global landscape is becoming more interconnected, competitive, and innovation-driven.

Companies that invest in digital transformation, strategic partnerships, and geographic diversification will be best positioned to succeed in this evolving market. Whether through new technologies, regulatory evolution, or strategic expansions, biologics outsourcing is at the center of the next wave of pharmaceutical growth.

Most Trending Reports By DataM Intelligence

[Biosimilars Market Size, Share Analysis 2025-2033](#)

[Antibody Drug Conjugates Market Size By 2031](#)

Sai Kiran

DataM Intelligence 4Market Research

+1 877-441-4866

Sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/816763280>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.